3-hydroxyflavone has been researched along with Retinal Diseases in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Armstrong, S; Beausejour, C; Beltran, PJ; Buscarlet, M; Cagnone, G; Chaney, SY; Crespo-Garcia, S; Dasgupta, S; Dejda, A; Dogan, T; Dubrac, A; Fournier, F; Girouard, G; Guber, V; Joyal, JS; Juneau, R; Mallette, FA; Marquess, D; O'Brien, R; Patel, P; Pilon, F; Rao, SR; Ryan, RD; Sapieha, P; Tsuruda, PR; Wilson, AM; Yohn, CB | 1 |
1 other study(ies) available for 3-hydroxyflavone and Retinal Diseases
Article | Year |
---|---|
Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition.
Topics: Animals; Apoptosis; bcl-X Protein; Cellular Senescence; Collagen Type I, alpha 1 Chain; Cyclin-Dependent Kinase Inhibitor p16; Disease Models, Animal; Endothelial Cells; Female; Flavonols; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Retinal Diseases; Tacrolimus | 2021 |